ANAPTYSBIO INC (ANAB)

US0327241065 - Common Stock

34.74  +1.52 (+4.58%)

After market: 34.74 0 (0%)

News Image
21 days ago - Market News Video

Notable Monday Option Activity: ANAB, AIR, FTI

News Image
2 months ago - AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

News Image
2 months ago - The Motley Fool

Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

News Image
2 months ago - Investor's Business Daily

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering

The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.

News Image
2 months ago - AnaptysBio, Inc.

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi

News Image
2 months ago - AnaptysBio, Inc.

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...

News Image
2 months ago - InvestorPlace

ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024

ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

News Image
2 months ago - BusinessInsider

ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the second quarter of 2024.A...

News Image
2 months ago - AnaptysBio, Inc.

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA...

News Image
5 months ago - InvestorPlace

ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024

ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image
5 months ago - BusinessInsider

ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the first quarter of 2024.An...

News Image
5 months ago - AnaptysBio, Inc.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by...

News Image
5 months ago - AnaptysBio, Inc.

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous...

News Image
6 months ago - Actym Therapeutics Inc.

Actym Therapeutics Appoints Thomas Smart as CEO

/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...

News Image
6 months ago - InvestorPlace

BTIG Research Predicts Over 118% Rally for These 3 Stocks

Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.

News Image
6 months ago - The Motley Fool

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

News Image
7 months ago - AnaptysBio, Inc.

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end...

News Image
8 months ago - AnaptysBio, Inc.

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...